A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine.
Phase of Trial: Phase IV
Latest Information Update: 29 Oct 2013
At a glance
- Drugs Insulin glargine; Insulin glulisine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms START
- Sponsors Sanofi
- 20 Mar 2012 Actual patient number is 493 according to ClinicalTrials.gov.
- 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2011 Planned End Date changed from 1 Jul 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.